ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
5 announcements with these filters
Senores Pharmaceuticals delivered strong Q1 FY27 growth, doubling approved ANDAs to 58. Management is pivoting strategy toward profitability in domestic branded generics while scaling US operations via new specialized subsidiaries.
Senores Pharmaceuticals delivered robust Q1FY27 performance with revenue growing 36% and EBITDA 87% YoY, driven by strong growth in regulated markets and margin expansion of ~800 bps.
Senores Pharmaceuticals delivered a blockbuster FY26, significantly outperforming guidance with 62% revenue growth and 108% PAT growth, driven by US regulated market expansion.
Senores delivered a massive FY26 beat across all primary metrics, fueled by aggressive US ANDA acquisitions and product launches. Management is hyper-optimistic, raising FY27 guidance significantly despite global logistical headwinds.
Senores Pharmaceuticals delivered strong FY26 performance with Total Income at ₹664 cr (+62% YoY) and PAT at ₹121.5 cr (+108% YoY), driven by regulated market scaling and strategic acquisitions.